Cerenome Inc CNSY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
-
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
-
Cerenome Launches CNSide® CSF Molecular Profile Tests
-
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
-
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
-
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
-
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
-
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Trading Information
- Previous Close Price
- $1.75
- Day Range
- $1.63–1.78
- 52-Week Range
- $1.49–18.89
- Bid/Ask
- $1.64 / $1.66
- Shares Outstanding
- 7.59M
- Market Cap
- $12.45M
- Volume/Avg
- 62,575 / 108,886
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.cerenome.com
Valuation
|
Metric
|
CNSY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CNSY
Financial Strength
|
Metric
|
CNSY
|
|---|---|
Quick Ratio | 1.23 |
Current Ratio | 1.37 |
Interest Coverage | −7.57 |
Quick Ratio
CNSY
Profitability
|
Metric
|
CNSY
|
|---|---|
Return on Assets (Normalized) | −145.01% |
Return on Equity (Normalized) | −389.66% |
Return on Invested Capital (Normalized) | −325.00% |
Return on Assets
CNSY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|pdqHm# | LOCK|?DjqZ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|s>PB?^ | LOCK|KV<s> | $83B | |||
| Moderna Inc
MRNA
| LOCK|@%p^$^V | LOCK|?$v | $80B | |||
| argenx SE ADR
ARGX
| LOCK|%v&N%BY | LOCK|$< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%ph^Qx | LOCK|KW | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|f?@>$& | LOCK|@fQgM | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|TTrG#>>^ | LOCK|K<&& | $28B | |||
| Incyte Corp
INCY
| LOCK|>J>>kV | LOCK|^@# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|z$z>>#r | LOCK|D@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|hs>%%b | LOCK|Q@ | $14B |
United States